Welcome to our dedicated page for Protalix BioTherapeutics SEC filings (Ticker: PLX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Protalix BioTherapeutics, Inc. filings document a commercial-stage biopharmaceutical issuer with NYSE American-listed common stock and a business built around recombinant therapeutic proteins produced through ProCellEx®. The company’s Form 8-K reports cover operating results, financial condition, business and clinical updates, corporate presentations, stockholder communications and regulatory events involving Elfabrio®.
Protalix’s proxy materials describe board governance, executive compensation, equity awards and shareholder voting matters. Its regulatory disclosures also identify material event reporting around European regulatory actions for Elfabrio, collaboration-related communications with commercialization partners, and the capital-market status of its common stock.
Protalix BioTherapeutics, Inc. (PLX) reported that director Aharon Schwartz received equity-based compensation on September 3, 2026. He was granted 17,000 stock options to buy common stock at an exercise price of $2.59 per share, expiring September 3, 2036, and 8,500 restricted stock units (RSUs). Both the options and RSUs vest in 12 equal quarterly installments commencing on the grant date, and each RSU represents one share of common stock upon vesting.
Protalix BioTherapeutics, Inc. (PLX) reported that senior vice president and chief operating officer Yaron Naos received new equity awards on September 3, 2026. He was granted options to buy 112,000 shares of common stock at an exercise price of $2.59 per share, expiring on September 3, 2036, vesting in 12 equal quarterly installments starting on the grant date. He also received 56,000 restricted stock units, each representing one share of common stock, which vest in 12 equal quarterly installments commencing on the grant date. Footnotes state that these figures do not include several existing option grants with different exercise prices and expiration dates.
Protalix BioTherapeutics, Inc. (PLX) reported that director Christian Elze received equity-based awards on September 3, 2026. He was granted 17,000 stock options to buy common stock at an exercise price of $2.59 per share and 8,500 restricted stock units, all held directly. The options and RSUs each vest in 12 equal quarterly installments commencing on the grant date. A separate footnote states he also holds options to purchase 15,000 shares at $1.64 per share expiring September 3, 2035. No Rule 10b5‑1 trading plan is reported for these awards.
Protalix BioTherapeutics, Inc. (PLX) reported that director Gwen A. Melincoff received equity awards on September 3, 2026. She was granted 17,000 stock options to buy common stock at an exercise price of $2.59 per share, expiring September 3, 2036, vesting in 12 equal quarterly installments from the grant date.
She was also granted 8,500 restricted stock units (RSUs), each representing one share of common stock, which vest in 12 equal quarterly installments from the grant date. Footnotes note additional outstanding option grants at various exercise prices and expirations that are not included in the post-transaction amounts shown for these awards.
Protalix BioTherapeutics, Inc. (PLX) reported that director Pol F. Boudes received equity compensation on September 3, 2026, consisting of options to purchase 17,000 shares of common stock at an exercise price of $2.59 per share, expiring September 3, 2036, and 8,500 restricted stock units.
The options and RSUs each vest in 12 equal quarterly installments, beginning on the grant date. Each RSU represents the right to receive one share of common stock upon vesting. No Rule 10b5-1 trading plan is reported in connection with these awards.
Protalix BioTherapeutics, Inc. (PLX) reported that its president and CEO, Dror Bashan, received equity-based compensation on September 3, 2026. He was granted 320,000 stock options to buy common stock at an exercise price of $2.59 per share, expiring on September 3, 2036, vesting in 12 equal quarterly installments beginning on the grant date, with potential accelerated vesting upon a corporate transaction or change in control under the company’s Amended and Restated 2006 Stock Incentive Plan. He was also granted 160,000 restricted stock units, each representing the right to receive one share of common stock after vesting, which also occurs in 12 equal quarterly installments beginning on the grant date. Following these grants, he holds 320,000 of these new options and 160,000 of these RSUs directly, and he also continues to hold previously granted options for 160,000 shares at $4.69 (expiring June 30, 2029), 750,000 shares at $1.03 (expiring September 7, 2032), and 340,000 shares at $1.64 (expiring September 3, 2035). No Rule 10b5-1 trading plan is reported for these awards.
Protalix BioTherapeutics, Inc. (PLX) reported that director Amos Bar-Shalev received equity-based compensation on September 3, 2026. He was granted stock options for 17,000 shares of common stock at an exercise price of $2.59 per share, expiring September 3, 2036, and 8,500 restricted stock units. Both the options and RSUs vest in 12 equal quarterly installments starting on the grant date, and no Rule 10b5-1 trading plan is reported.
Protalix BioTherapeutics, Inc. (PLX) reported that director Ben Zvi Shmuel received equity-based compensation on September 3, 2026. He was granted 17,000 stock options with an exercise price of $2.59 per share, expiring on September 3, 2036, which vest in 12 equal quarterly installments starting on the grant date.
He was also granted 8,500 restricted stock units, each representing the right to receive one share of common stock after vesting, which likewise vest in 12 equal quarterly installments commencing on the grant date. A footnote states that he also holds prior option grants for additional shares at exercise prices between $1.03 and $1.66 with expirations from June 30, 2032 through September 3, 2035.
Protalix BioTherapeutics, Inc. (PLX) reported that director Eliot Forster received equity awards on September 3, 2026. He was granted stock options for 17,000 shares of common stock at an exercise price of $2.59 per share, expiring September 3, 2036, vesting in 12 equal quarterly installments from the grant date. He was also granted 8,500 restricted stock units, each representing one share of common stock, which also vest in 12 equal quarterly installments from the grant date. Separately, he already holds options for 85,715 shares at $1.75 expiring September 14, 2033 and 15,000 shares at $1.64 expiring September 3, 2035.
Protalix BioTherapeutics reported sharply improved results for the six months ended June 30, 2026. Total revenue was $53.6 million, up from $25.8 million a year earlier, driven mainly by a $25.0 million milestone from Chiesi tied to EU approval of the every‑four‑weeks Elfabrio dosing regimen and higher Elfabrio product sales. Revenue from selling goods rose to $27.2 million, with increased sales to Chiesi and Fiocruz partly offset by lower Pfizer orders following unusually high 2025 purchases.
The company generated operating income of $25.8 million versus a prior‑year loss, and net income of $22.1 million (basic EPS $0.28) versus a $3.5 million loss. A new Israeli R&D grant reduced reported R&D expense by $2.1 million. Cash and cash equivalents were $27.4 million and, together with short‑term deposits, totaled about $40.7 million, supporting management’s view that liquidity is sufficient for at least 12 months. The company highlights ongoing geopolitical risks in Israel, potential impacts from new U.S. pharma tariffs, and uncertainty around future Israeli R&D grants, but notes that recent regional conflicts have not yet had a material adverse effect on its operations.